StemCell Institute Inc.
株式会社ステムセル研究所
Valuation
Fundamental ratios for the latest reported period.
Ticker: 7096
FY2025 (Mar 2026) · J-GAAP · consolidated Source: filing S100YI32
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (Mar 2026) runs Apr 1, 2025 – Mar 31, 2026.
| Gross margin | 60.9% |
|---|---|
| Operating margin | 7.2% |
| Net margin | 5.5% |
| Return on equity | 5.8%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 1.9% |
| Revenue growth (YoY) | —Consolidation scope changed from the prior year |
| EPS (basic) | ¥15.44 |
| EPS growth (YoY) | —Consolidation scope changed from the prior year |
| Current ratio | 1.17x |
| Equity ratio | 33.0% |
| Book value / share | ¥266.34 |
| Free cash flow | −¥453M |